ライフサイエンスコーパス: leukapheresis

1 eria because of comorbidities at the time of leukapheresis.

2 cells were collected using a novel method of leukapheresis.

3 actor 5ug/kg/day for 5 days and collected by leukapheresis.

4 019, 71 patients were enrolled and underwent leukapheresis.

5 could replace centrifugation for performing leukapheresis.

6 damustine given within 6 versus 12 months of leukapheresis.

7 rial because of comorbidities at the time of leukapheresis.

8 cipant in the MesoPher group did not undergo leukapheresis.

9 timately enable centrifugation-free, low-ECV leukapheresis.

10 errogate the HIV reservoir in vitro requires leukapheresis.

11 ous latent HIV reservoirs without performing leukapheresis.

12 CACs and EPCs were efficiently harvested by leukapheresis.

13 storing large numbers of angiogenic cells by leukapheresis.

14 lating factor (hG-CSF) and were collected by leukapheresis.

15 d to G-CSF, intravenous device insertion, or leukapheresis.

16 lood, and cytokine-elicited peripheral blood leukapheresis.

17 al blood mononuclear cells were harvested by leukapheresis.

18 (+) peripheral blood stem cells harvested by leukapheresis.

19 Of 189 patients who underwent leukapheresis, 168 (89%) received brexu-cel infusion.

20 Of 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy.

21 By day 5 of leukapheresis, 63% of the patients treated with SCF plus

22 DPBSCs were obtained by leukapheresis after mobilization with granulocyte-colony

23 A total of 17 allo-SCT donors received leukapheresis and 14 patients with B-ALL (median age, 43

24 Overall, 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel, of whi

25 40 patients underwent leukapheresis and 38 (95%) had CAR T-cell products manuf

26 the primary analysis), 74 patients underwent leukapheresis and 61 received lisocabtagene maraleucel (

27 cturing quality standards for both mobilized leukapheresis and bone marrow, and reconstitute human ha

28 After leukapheresis and conditioning chemotherapy, patients re

29 inib was scheduled to begin >=2 weeks before leukapheresis and continue for >=3 months after CAR T-ce

30 Ibrutinib commenced before leukapheresis and continued through CAR-T manufacture fo

31 We utilized leukapheresis and countercurrent centrifugal elutriation

32 treatment with G-CSF for 5 days followed by leukapheresis and intravenous infusion of three doses of

33 Leukapheresis and macrophage infusion were well tolerate

34 ould be primed by various factors related to leukapheresis and mobilization that increase its associa

35 Patients underwent leukapheresis and optional bridging therapy, followed by

36 Patients underwent leukapheresis and received conditioning chemotherapy (cy

37 Patients underwent leukapheresis and received lymphodepleting chemotherapy

38 Patients underwent leukapheresis and subsequent lapuleucel-T infusion 2 day

39 Among 28 enrolled patients, all underwent leukapheresis and successful CAR-T manufacturing, althou

40 20, 153 patients were enrolled and underwent leukapheresis, and axicabtagene ciloleucel was successfu

41 (PBPC) were cytokine-mobilized, collected by leukapheresis, and cryopreserved using 5% dimethyl sulfo

42 lating factor, collected by peripheral blood leukapheresis, and purified away from contaminating lymp

43 cyte colony-stimulating factor, harvested by leukapheresis, and purified by magnetic-activated cell s

44 ng factor)-mediated CD34+ cell mobilization, leukapheresis, and selective 1x10(5) CD34+ cells/kg infu

45 lected from patients with RRMM who underwent leukapheresis as of February 28, 2022, at 11 US institut

46 with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institu

47 ne 16, 2022, 137 enrolled patients underwent leukapheresis at 27 sites in the USA.

48 clear cells from mobilized blood obtained by leukapheresis at day 4 after initiation of G-CSF (G-PBMC

49 Leukapheresis began on day 5 of cytokine administration

50 Patients who underwent leukapheresis between August 1, 2020 and December 31, 20

51 We further show that diagnostic leukapheresis can be easily combined with the US Food an

52 Clinical leukapheresis can concentrate mononuclear cells from alm

53 /laboratory findings and their impact on the leukapheresis cell composition.

54 receive APC8015F, a product made with frozen leukapheresis cells.

55 increased IL-1beta production in stimulated leukapheresis concentrates and peripheral blood samples

56 ral blood mononuclear cells were obtained by leukapheresis, depleted of monocytes, and cultured in th

57 A were compared to classic QVOA using single leukapheresis-derived samples from five ART-suppressed H

58 irculating Tregs were isolated from blood or leukapheresis, expanded under good manufacturing practic

59 Leukapheresis followed by a two-step cell isolation proc

60 /R iNHL after >=2 lines of therapy underwent leukapheresis, followed by lymphodepleting chemotherapy

61 taxel plus ifosfamide were administered with leukapheresis, followed by three cycles of carboplatin p

62 amide 6 g/m(2) were given 2 weeks apart with leukapheresis, followed by three cycles of carboplatin p

63 Immunosuppression was discontinued before leukapheresis for CART and not reinitiated ever since.

64 Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 1 Marc

65 utaneous technique in 15 children undergoing leukapheresis for collection of autologous peripheral bl

66 16, and July 5, 2019, 344 patients underwent leukapheresis for manufacture of CAR(+) T cells (liso-ce

67 CD8(+) T cells obtained by leukapheresis from 10 patients with disseminated HLA-A2.

68 QVOA on resting CD4(+) T cells obtained via leukapheresis from 37 human immunodeficiency virus (HIV)

69 eripheral blood mononuclear cells (PBMCs) by leukapheresis from a 55-year-old man with chronic HIV in

70 ral blood stem cells (PBSC) were obtained by leukapheresis from a human male donor after 4 days of ad

71 blood mobilized progenitor cells obtained by leukapheresis from both major histocompatibility complex

72 obilized progenitor cells (PBPC) obtained by leukapheresis from MHC-inbred miniature swine (n=6) were

73 blood mononuclear cells (PBMCs) derived from leukapheresis from patients enrolled in the Baltimore Lo

74 east 1.75x10(7) CD34 cells were harvested by leukapheresis from patients in each study cohort.

75 ndamustine exposure (within 24 months before leukapheresis) had shorter PFS and overall survival afte

76 neutrophils in donors before centrifugation leukapheresis has rekindled interest in the potential cl

77 mly assigned participants, and who underwent leukapheresis if they were in the MesoPher group.

78 Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT.

79 ultimately enable low extracorporeal volume leukapheresis in children.

80 ) had shorter PFS and overall survival after leukapheresis in intention-to-treat univariable analysis

81 Dendritic-cell precursors were harvested by leukapheresis in weeks 0, 4, 8, and 24, loaded ex vivo w

82 ear cell depletion by leukapheresis, or sham leukapheresis, in a double-blind fashion (15 volunteers

83 Leukapheresis is a potentially life-saving therapy for c

84 our study suggests that microfluidics-based leukapheresis is safe and effective at selectively remov

85 Because leukapheresis (LA) targets peripheral blood mononuclear

86 per day for 5 days followed by large-volume leukapheresis (LVL).

87 Eligible adults underwent leukapheresis, lymphodepleting chemotherapy, and axi-cel

88 lded a median of 194 x 10(6) CD34+ cells per leukapheresis (n = 7).

89 uantify and compare Th1 and Th2 responses of leukapheresis-obtained peripheral blood mononuclear cell

90 Thus, the initial enrichment by routine leukapheresis of mononuclear cells from very large blood

91 were collected by 2-hour single-blood volume leukapheresis on 2 consecutive days at the time of hemat

92 or 5 microg x kg(-1) x d(-1) for 5 days with leukapheresis on the fifth day.

93 Bruton tyrosine kinase inhibitor) underwent leukapheresis, optional bridging therapy, and conditioni

94 Cs from different sources (phlebotomy versus leukapheresis) or using total or resting CD4(+)T cells p

95 receive active mononuclear cell depletion by leukapheresis, or sham leukapheresis, in a double-blind

96 Well-tolerated by adults, leukapheresis poses a significant risk to neonates and l

97 We therefore turned to leukapheresis posttransplant to improve absolute yield.

98 ved DC vaccines were prepared after a single leukapheresis procedure and administered intradermally a

99 cytokine-mobilized animals via an automated leukapheresis procedure demonstrated a 10-fold increase

100 Factors relating to the leukapheresis procedure, including cell collection proce

101 eduction) by the end of a 3.5-hour simulated leukapheresis procedure.

102 median progenitor cell yield from the 3-day leukapheresis procedure.

103 d more CD8(+) effector memory T cells in the leukapheresis product compared with G-CSF alone.

104 with as much as a 4.0-fold enrichment in the leukapheresis product compared with G-CSF alone.

105 Similarly, CD34+ cells isolated from the leukapheresis product did not differ significantly in im

106 fold more CD34+ cells were isolated from the leukapheresis product of animals receiving G-CSF or G-CS

107 cells isolated from the bone marrow (BM) and leukapheresis product of cytokine-mobilized nonhuman pri

108 -iChip, that rapidly sorts through an entire leukapheresis product of over 6 billion nucleated cells,

109 CD25 Treg cells were selected from leukapheresis product with a GMP-compliant cell separati

110 unoadsorptive system from the BM, PB, and/or leukapheresis product.

111 O-CD27+CD8+ T cells in the pre-manufacturing leukapheresis product.

112 l the Provenge that could be prepared from a leukapheresis product.

113 ule generates higher CD34+ cell yield in the leukapheresis product.

114 CD14 cells derived from leukapheresis products (G-CD14 cells) suppressed alloant

115 marrow (NBM), umbilical cord blood (CB), and leukapheresis products (LP).

116 We found that supernatants of leukapheresis products (SLPs) of patients mobilized with

117 may be also qualitative differences between leukapheresis products and marrow.

118 the large proportion of monocytes present in leukapheresis products could contribute to the unexpecte

119 in why HSPCs from mobilized peripheral blood leukapheresis products engraft more quickly in patients

120 isolated CD34(+) cells from peripheral blood leukapheresis products infected under the same condition

121 Tumor cells were detected in leukapheresis products of eight patients: three in the G

122 CD14 monocytes isolated from leukapheresis products of Macacca mulatta were cultured

123 4+ cells were determined in one blood volume leukapheresis products of six normal individuals given G

124 Examination of the T-cell subsets in the leukapheresis products showed three different patterns:

125 ed before cytokine infusion, and one to five leukapheresis products were tested for the presence of t

126 were tumor-positive, and in eight patients, leukapheresis products were tumor-positive.

127 y this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volum

128 accumulation of these cells in the resulting leukapheresis products.

129 obilization blood samples were compared with leukapheresis products.

130 In addition to the potential for reduced leukapheresis-related morbidity and costs, SCF offers ad

131 harvest stem cells for transplantation is by leukapheresis, requiring mobilization of CD34+ hematopoi

132 At the time of leukapheresis, responders presented elevated levels of C

133 (8 mg orally) given 12 hours before standard leukapheresis routinely results in the collection of app

134 Leukapheresis samples from four fully ART-suppressed, ch

135 ALL across 15 US institutions, who underwent leukapheresis shipment to Novartis for commercial tisage

136 The quality and characteristics of the leukapheresis starting material has been identified as a

137 manufactured from autologous patient-derived leukapheresis starting material.

138 that might affect the quality of autologous leukapheresis starting materials.

139 ose of granulocytes obtainable with standard leukapheresis techniques has been inadequate.

140 nt donor stimulation regimens and suboptimal leukapheresis techniques.

141 e typical parameters of centrifugation-based leukapheresis, the CIF device had a void volume at least

142 Leukapheresis, the extracorporeal separation of white bl

143 A leukapheresis to obtain peripheral-blood mononuclear cel

144 A leukapheresis to obtain peripheral-blood mononuclear cel

145 verall survival for all 344 patients who had leukapheresis was 18.8 months (95% CI 15.0-19.3).

146 Leukapheresis was performed beginning on day 5 of cytoki

147 Leukapheresis was performed on day 6, and yielded a medi

148 Donor leukapheresis was performed on the 5th postoperative day

149 Leukapheresis was performed on the final 3 days of cytok

150 Leukapheresis was performed to harvest peripheral-blood

151 of 240 mug/kg by subcutaneous injection, and leukapheresis was then initiated just 4 hours later.

152 lls obtained before and after vaccination by leukapheresis were analyzed using a fluorescence-based H

153 CD34-enriched cells from the leukapheresis were predominantly myeloid-committed, but

154 plasma samples from 122 patients at time of leukapheresis who received standard-of-care CART19 for r

155 Leukapheresis yields averaged 2.8 x 10(8) peripheral blo

156 tration of G-CSF, has significantly enhanced leukapheresis yields.